Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00474994 · ClinicalTrials.gov registry record · Phase 2
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
A Phase 2 study of Ovarian Cancer and Endometrial Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 2
- Study locations
NCT00474994: Completed Phase 2 study of Ovarian Cancer and Endometrial Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00474994 is a Phase 2 study of Ovarian Cancer and Endometrial Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 53 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00474994, a Phase 2 study of Ovarian Cancer and Endometrial Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with metastatic, locally advanced, or locally recurrent sarcomas.
Primary Outcome
as assessed by RECIST criteria
Conditions Studied
Interventions
- DRUG sunitinib malate
Study Locations (2)
Massachusetts
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2007-04 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
What the finished NCT00474994 record still lists
NCT00474994 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (93% lower).
The record links to 6 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which sunitinib malate is the first listed.
NCT00474994 reports a single indexed study location in Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT00474994 about?
NCT00474994 is a clinical study titled "Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas". RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with metastatic, locally advanced, or locally recurrent sarc...
What is the current status of trial NCT00474994?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2007-04. Estimated completion is 2010-11.
What conditions does trial NCT00474994 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Sarcoma, Small Intestine Cancer, Desmoid Tumor.
What interventions are being tested in trial NCT00474994?
The interventions under investigation include: sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT00474994?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00474994 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00474994's enrollment target sits among peer trials
53 206th of 322 higher than 117 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia